BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
CALSCALE:GREGORIAN
PRODID:-//WordPress - MECv6.8.15//EN
X-ORIGINAL-URL:https://stage.utoronto.ca/
X-WR-CALNAME:CANSSI Ontario STAGE
X-WR-CALDESC:
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-PUBLISHED-TTL:PT1H
X-MS-OLK-FORCEINSPECTOROPEN:TRUE
BEGIN:VEVENT
CLASS:PUBLIC
UID:MEC-3e1fb9297735057d44263e674078a7fd@stage.utoronto.ca
DTSTART:20130405T160000Z
DTEND:20130405T170000Z
DTSTAMP:20250718T225300Z
CREATED:20250718
LAST-MODIFIED:20260316
PRIORITY:5
SEQUENCE:161
TRANSP:OPAQUE
SUMMARY:STAGE ISSS: Mathieu Lupien
DESCRIPTION:\nJoin us for the next instalment of the STAGE International Speaker Seminar Series (ISSS) with\n\n\n\nMathieu Lupien \n\n\n\nScientist, Ontario Cancer InstituteAssistant Professor, Department of Medical Biophysics, University of TorontoInvestigator, Ontario Institute for Cancer Research\n\n\n\nTalk Title:\n\n\n\nEpigenomics reveal the function of genetic risk-variants in cancer \n\n\n\nAbstract:\n\n\n\nGenome-wide association studies (GWAS) have identified thousands of SNPs that are associated with human traits and diseases.  But, because the vast majority of these SNPs are located in non-coding  regions of the genome, the mechanisms by which they promote disease  risk have remained elusive. Employing a new methodology that combines  cistromics, epigenomics and genotype imputation, we annotate the noncoding regions of the genome in breast cancer cells and systematically  identify the functional nature of SNPs associated with breast cancer risk.  Our results show that breast cancer risk-associated SNPs are enriched  in the cistromes of FOXA1 and ESR1 and the epigenome of histone H3  lysine 4 monomethylation (H3K4me1) in a cancer- and cell type-specific  manner. Furthermore, the majority of the risk-associated SNPs modulate  the affinity of chromatin for FOXA1 at distal regulatory elements, thereby  resulting in allele-specific gene expression, which is exemplified by the  effect of the rs4784227 SNP on the TOX3 gene within the 16q12.1 risk  locus.\n\n\n\nSpeaker Profile:\n\n\n\nMathieu Lupien has been scientist at the Ontario Cancer Institute  (OCI) and cross-appointed to the Ontario Institute for Cancer Research  (OICR) since 2012. He earned his Ph.D. at McGill University in 2005,  followed by a post-doctoral training at the Dana-Farber Cancer Institute,  Harvard Medical School in Boston, MA as an Era of Hope fellow. Lupien  completed his post-doctoral training in medical oncology in 2008. In  2009, Dr. Lupien was recruited as a faculty member at Dartmouth Medical  School, in Hannover, NH where he became Director of the Quantitative  Epigenomics laboratory. Dr. Lupien has co-authored approximately 30  peer-reviewed publications in his short career, including seminal work  reported in high-impact journals including Science, Cell, Nature Genetics  and The Journal of the National Cancer Institute. Among other honors,  Dr. Lupien is a recipient of the Young Investigator Award from the Ontario  Institute for Cancer Research.\n\n\n\nSpeaker Poster:\n\n\n\n\n\n\n\nMathieu Lupien Poster ( https://stage.utoronto.ca/wp-content/uploads/2025/07/Lupien-Mathieu-Poster.pdf )Download\n\n\n\nPhotography Disclosure:\n\n\n\nPhotographs and/or video may be taken of participants at STAGE events. These photos/videos are for the Program’s use only and may appear on its website, in printed brochures, or in other promotional or reporting materials. By attending STAGE events, you accept the possibility that you may be videotaped or photographed. If you have any concerns, please inform us by sending an e-mail to esther.berzunza@utoronto.ca\n
URL:https://stage.utoronto.ca/events/stage-isss-mathieu-lupien/
ORGANIZER;CN=CANSSI Ontario:MAILTO:esther.berzunza@utoronto.ca
CATEGORIES:CANSSI Ontario STAGE ISSS
LOCATION:4th Floor, Elm Wing, 555 University Ave, Toronto, ON
ATTACH;FMTTYPE=image/png:https://stage.utoronto.ca/wp-content/uploads/2025/07/Lupien-Mathieu.png
END:VEVENT
END:VCALENDAR